Generated by AI
AN2 Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing novel small-molecule therapeutics derived from its boron chemistry platform. The company’s current pipeline includes programs in infectious diseases, hematologic disorders, and oncology, with research efforts aimed at addressing serious and rare conditions with high unmet medical needs. Its product candidates include oral therapies under development for diseases such as Chagas disease, non-tuberculous mycobacterial lung disease, and other infectious disease targets, alongside earlier-stage oncology and global health programs. AN2 Therapeutics operates as a drug discovery and development business, advancing its candidates through preclinical and clinical studies to support potential future therapies for patients and healthcare providers.
Website1300 El Camino Real
Menlo Park, CA, 94025
United States
The latest articles about ANTX.
MENLO PARK, Calif., November 04, 2026--AN2 Therapeutics, Inc. (NASDAQ: ANTX), a clinical-stage biopharmaceutical company discovering and developing novel small molecule therapeutics derived from its boron chemistry platform, today announced the advancement of AN2-504661, a novel boron-based ENPP1 inhibitor, as a development candidate for the treatment of HPP.
Summary of Mar 18's posts. Generated by AI.
Summary of Mar 10's posts. Generated by AI.
Summary of Mar 9's posts. Generated by AI.
No summary yet.
Summary of Mar 10's posts. Generated by AI.
Investors talking about ANTX also mention these. Each card shows that asset’s own numbers for the past 24 hours.
Valuation and earnings.